X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7067) 7067
Newsletter (238) 238
Newspaper Article (135) 135
Book Chapter (27) 27
Magazine Article (22) 22
Publication (12) 12
Dissertation (7) 7
Conference Proceeding (4) 4
Transcript (4) 4
Book / eBook (1) 1
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rivaroxaban (6489) 6489
humans (4018) 4018
dabigatran (2804) 2804
warfarin (2459) 2459
anticoagulants (2425) 2425
apixaban (2181) 2181
atrial fibrillation (1861) 1861
male (1746) 1746
female (1685) 1685
anticoagulants - therapeutic use (1684) 1684
administration, oral (1490) 1490
aged (1395) 1395
stroke (1323) 1323
venous thromboembolism (1265) 1265
prevention (1203) 1203
hematology (1198) 1198
thromboembolism (1190) 1190
anticoagulants - administration & dosage (1187) 1187
anticoagulants - adverse effects (1173) 1173
cardiac & cardiovascular systems (1154) 1154
middle aged (1116) 1116
peripheral vascular disease (1099) 1099
atrial fibrillation - drug therapy (988) 988
treatment outcome (928) 928
risk factors (851) 851
hemorrhage - chemically induced (822) 822
stroke - prevention & control (817) 817
rivaroxaban - therapeutic use (811) 811
safety (796) 796
thrombosis (793) 793
risk (762) 762
pharmacology & pharmacy (750) 750
atrial-fibrillation (722) 722
medicine, general & internal (717) 717
atrial fibrillation - complications (696) 696
morpholines - therapeutic use (692) 692
thiophenes - therapeutic use (687) 687
management (679) 679
research (650) 650
aged, 80 and over (649) 649
anticoagulation (646) 646
care and treatment (645) 645
bleeding (635) 635
oral anticoagulants (611) 611
abridged index medicus (610) 610
analysis (610) 610
dabigatran etexilate (601) 601
pyridones - therapeutic use (577) 577
pyrazoles - therapeutic use (575) 575
factor xa inhibitors (573) 573
edoxaban (566) 566
factor xa inhibitors - therapeutic use (562) 562
warfarin - therapeutic use (559) 559
rivaroxaban - administration & dosage (558) 558
patients (553) 553
enoxaparin (549) 549
adult (547) 547
therapy (546) 546
drug therapy (538) 538
rivaroxaban - adverse effects (530) 530
aspirin (509) 509
cardiac arrhythmia (499) 499
thrombin (491) 491
stroke prevention (481) 481
thromboprophylaxis (481) 481
direct oral anticoagulants (480) 480
medical research (465) 465
pharmacokinetics (455) 455
beta-alanine - analogs & derivatives (446) 446
stroke - etiology (442) 442
medicine & public health (437) 437
venous thromboembolism - prevention & control (435) 435
medicine, experimental (431) 431
double-blind (429) 429
deep-vein thrombosis (428) 428
surgery (428) 428
retrospective studies (426) 426
hemorrhage (425) 425
morpholines - administration & dosage (417) 417
thiophenes - administration & dosage (417) 417
venous thromboembolism - drug therapy (413) 413
efficacy (407) 407
morpholines - adverse effects (400) 400
factor xa inhibitors - administration & dosage (399) 399
thiophenes - adverse effects (399) 399
factor xa inhibitors - adverse effects (398) 398
vitamin k - antagonists & inhibitors (398) 398
dosage and administration (389) 389
blood coagulation - drug effects (388) 388
clinical trials (384) 384
factor xa inhibitor (384) 384
pyridones - administration & dosage (384) 384
pyrazoles - administration & dosage (383) 383
mortality (379) 379
cardiology (371) 371
antithrombotic therapy (370) 370
benzimidazoles - therapeutic use (369) 369
anticoagulants - pharmacology (366) 366
warfarin - adverse effects (361) 361
pulmonary embolism (360) 360
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6666) 6666
German (247) 247
French (153) 153
Russian (128) 128
Spanish (119) 119
Japanese (56) 56
Czech (42) 42
Polish (26) 26
Italian (25) 25
Portuguese (24) 24
Chinese (21) 21
Hungarian (19) 19
Korean (17) 17
Swedish (10) 10
Turkish (10) 10
Slovenian (5) 5
Dutch (4) 4
Finnish (3) 3
Norwegian (3) 3
Slovak (3) 3
Danish (2) 2
Croatian (1) 1
Estonian (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 14, pp. 1319 - 1330
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
by Anand, Sonia S and Bosch, Jackie and Eikelboom, John W and Connolly, Stuart J and Aboyans, Victor and Alings, Marco and Kakkar, Ajay K and Lewis, Basil S and Störk, Stefan and Zhu, Jun and Lopez-Jaramillo, Patricio and O'Donnell, Martin and Commerford, Patrick J and Vinereanu, Dragos and Ryden, Lars and Misselwitz, Frank and Varigos, John D and Vanassche, Thomas and Chen, Edmond and Branch, Kelley and Leong, Darryl P and Bangdiwala, Shrikant I and Hart, Robert G and Yusuf, Salim and CARTASEGNA, LUIS and VICO, MARISA and HOMINAL, MIGUEL ANGEL and HASBANI, EDUARDO and CACCAVO, ALBERTO and VOGEL, DANIEL and HRABAR, ADRIAN and CUNEO, CARLOS and MACKINNON, IGNACIO J and AHUAD GUERRERO, RODOLFO ANDRES and COSTABEL, JUAN PABLO and BARTOLACCI, INES PALMIRA and BARBIERI, MARIA and GOMEZ VILAMAJO, OSCAR and GARCIA DURAN, RUBEN OMAR and SCHIAVI, LILIA BEATRIZ and INGARAMO, ADRIAN and BORDONAVA, ANSELMO PAULINO and PELAGAGGE, MARIA JOSE and NOVARETTO, LEONARDO and ALBISU DI GENNERO, JUAN PABLO and IBANEZ SAGGIA, LUZ MARIA and ALVAREZ, MOIRA and VITA, NESTOR ALEJANDRO and MACIN, STELLA MARIS and CARDONA, MARCELO and SARJANOVICH, RODOLFO JUAN and CUADRADO, JESUS and LITVAK BRUNO, MARCOS RAUL and CHACON, CAROLINA and MAFFEI, LAURA ELENA and GRINFELD, DIEGO and VENSENTINI, NATALIA and MAJUL, CLAUDIO RODOLFO and LUCIARDI, HECTOR LUCAS and FERRE PACORA, FREDY ANTONI and VAN DEN HEUVEL, PAUL and VERHAMME, PETER and DEBONNAIRE, PHILIPPE and VAN DE BORNE, PHILIPPE and LEROY, JEAN and SCHROE, HERMAN and ELEGEERT, IVAN and HOFFER, ETIENNE and DUJARDIN, KARL and ABRANTES, JOSE ANTONIO and MANENTI, EULER and MAIA, LILIA and HERNANDES, MAURO and ROSSI DOS SANTOS, FABIO and ZIMMERMANN, SERGIO LUIZ and ABIB JR, EDUARDO and LEAES, PAULO and BOTELHO, ROBERTO and BRAILE, MARIA and IZUKAWA, NILO and TANAJURA, LUIZ FERNANDO and SERRANO JUNIOR, CARLOS VICENTE and NASI, LUIZ ANTONIO and TYTUS, RICHARD and PANDEY, SHEKHAR and LONN, EVA and CHA, JAMES and BABAPULLE, MOHAN and LAMY, ANDRE and KIAII, BOB and BHARGAVA, RAKESH and MEHTA, PRAVINSAGAR and HILL, LAURIE and FELL, DAVID and LAM, ANDY and AL-QOOFI, FAISAL and PETRELLA, ROBERT and GLANZ, ANTHONY and NOISEUX, NICOLAS and MERALI, FATIMA and ... and COMPASS Investigators and Sahlgrenska akademin and Institute of Medicine, Department of Molecular and Clinical Medicine and Institutionen för medicin, avdelningen för molekylär och klinisk medicin and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy
The Lancet (British edition), ISSN 0140-6736, 2018, Volume 391, Issue 10117, pp. 219 - 229
Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | MANAGEMENT | THERAPY | OUTPATIENTS | CARDIOVASCULAR EVENT RATES | PREVENTION | RISK | Myocardial Infarction - epidemiology | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Carotid Artery Diseases - complications | Male | Peripheral Arterial Disease - complications | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Dose-Response Relationship, Drug | Rivaroxaban - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Stroke - epidemiology | Aspirin - therapeutic use | Lower Extremity - surgery | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Myocardial Infarction - etiology | Rivaroxaban - therapeutic use | Carotid Artery Diseases - drug therapy | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Peripheral Arterial Disease - drug therapy | Carotid Artery Diseases - epidemiology | Morbidity | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Peripheral Arterial Disease - epidemiology | Factor Xa Inhibitors - adverse effects | Aged | Myocardial Infarction - prevention & control | Amputation - statistics & numerical data | Hemorrhage - chemically induced | Lower Extremity - blood supply | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Heart attacks | Medical imaging | Mortality | Clinical trials | Cardiovascular disease | Patients | Disease control | Evidence-based medicine | Carotid arteries | Disease prevention | Coronary vessels | Blood pressure | Carotid artery | Acute coronary syndromes | Thromboembolism | Health risk assessment | Cardiovascular Diseases | Factor Xa Inhibitors | Klinisk medicin | Hemorrhage | epidemiology | Rivaroxaban | administration & dosage | Combination | Amputation | Drug | drug therapy | chemically induced | complications | prevention & control | Peripheral Arterial Disease | etiology | Clinical Medicine | Myocardial Infarction | statistics & numerical data | blood supply | Carotid Artery Diseases | Platelet Aggregation Inhibitors | adverse effects | mortality | Lower Extremity | Dose-Response Relationship | therapeutic use | surgery
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 379, Issue 12, pp. 1118 - 1127
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 25, pp. 2423 - 2434
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 23, pp. 2191 - 2201
In a randomized trial involving patients who had a first stroke from an embolus of unknown source, rivaroxaban at a daily dose of 15 mg did not result in a... 
CRYPTOGENIC STROKE | TRIALS | MEDICINE, GENERAL & INTERNAL | DESIGN | METAANALYSIS | EFFICACY | WARFARIN | SAFETY | ANTITHROMBOTIC THERAPY | FORAMEN OVALE CLOSURE | ATRIAL-FIBRILLATION | Stroke - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Brain Ischemia - prevention & control | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Stroke - etiology | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Intracranial Embolism - drug therapy | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke (Disease) | Prevention | Rivaroxaban | Complications and side effects | Dosage and administration | Drug therapy | Hemorrhage | Risk factors | Cardiac arrhythmia | Neurosciences | Embolisms | Stenosis | Bleeding | Design | Ischemia | Atherosclerosis | Drug dosages | Research centers | Anticoagulants | Medical research | Stroke | Aspirin | Internal medicine | Research & development--R&D | Thrombosis | Patients | Embolism | Blood clots | Medicine | Neurology | Hospitals | Life Sciences | Human health and pathology | metaanalysis | atrial-fibrillation | foramen ovale closure | antithrombotic therapy | Klinisk medicin | efficacy | warfarin | Clinical Medicine | trials | safety | design | cryptogenic stroke | General & Internal Medicine
Journal Article